Chadds Ford-based Endo Pharmaceuticals will make its Opana ER pain drug crush-resistant.
The move helps reduce the drug’s potential for abuse and has been approved by the FDA, according to the Philadelphia Business Journal.
Endo will make the transition in 2012, but little else will change. Opana ER will have the same name, color, size, shape, packaging and dosage. The current Opana ER tablets are taken whole and could be potentially fatal if crushed.